Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Br J Pharmacol
2001 Oct 01;1343:496-506. doi: 10.1038/sj.bjp.0704263.
Show Gene links
Show Anatomy links
The role of the hydrophilic Asn230 residue of the mu-opioid receptor in the potency of various opioid agonists.
Pil J
,
Tytgat J
.
???displayArticle.abstract???
1. To investigate the effect of the hydrophilic Asn amino acid at position 230 of the human mu-opioid receptor (hMOR230) on the potency of various agonists, we mutated this residue to Thr and Leu (hMORN230T and hMORN230L respectively). 2. Taking advantage of the functional coupling of the opioid receptor with the heteromultimeric G-protein-coupled inwardly rectifying K(+) (GIRK1/GIRK2) channel, either the wild type hMOR or one of the mutated receptors (hMORN230L or hMORN230T) were functionally coexpressed with GIRK1/GIRK2 channels and a regulator of G-protein signalling (RGS4) in Xenopus laevis oocytes. 3. The two-microelectrode voltage clamp technique was used to measure the opioid receptor-activated GIRK1/GIRK2 channel responses. The potency of [D-Ala(2),N-MePhe(4),Gly(5)-ol]-enkephalin (DAMGO), remained unaffected as measured via hMORN230T and hMORN230L, while the potency of fentanyl and morphine significantly increased via these mutated receptors. 4. Our results are indicative for the existence of hydrophobic interactions between a methyl-group of the side chain of Thr or Leu on the one hand and the piperidine-ring of fentanyl and the hexene-ring of morphine on the other. The mutations also had no influence on the potency of morphine-6-glucuronide (M6G) and morphine-3-glucuronide (M3G). 5. We conclude that the hydrophilic side chain of Asn in position 230 is not involved in the formation of a H-bond with the aliphatic alcohol of morphine and that an enhancement of the potency of morphine and fentanyl can be explained by mutating this residue towards more hydrophobic amino acids.
Befort,
The conserved aspartate residue in the third putative transmembrane domain of the delta-opioid receptor is not the anionic counterpart for cationic opiate binding but is a constituent of the receptor binding site.
1996, Pubmed
Befort,
The conserved aspartate residue in the third putative transmembrane domain of the delta-opioid receptor is not the anionic counterpart for cationic opiate binding but is a constituent of the receptor binding site.
1996,
Pubmed
Black,
Development of hydrophobicity parameters to analyze proteins which bear post- or cotranslational modifications.
1991,
Pubmed
Chaturvedi,
mu Opioid receptor: role for the amino terminus as a determinant of ligand binding affinity.
2000,
Pubmed
Chen,
Determination of the amino acid residue involved in [3H]beta-funaltrexamine covalent binding in the cloned rat mu-opioid receptor.
1996,
Pubmed
De Vries,
The regulator of G protein signaling family.
2000,
Pubmed
Derrick,
3-Deoxyclocinnamox: the first high-affinity, nonpeptide mu-opioid antagonist lacking a phenolic hydroxyl group.
2000,
Pubmed
Doupnik,
RGS proteins reconstitute the rapid gating kinetics of gbetagamma-activated inwardly rectifying K+ channels.
1997,
Pubmed
,
Xenbase
Evans,
Cloning of a delta opioid receptor by functional expression.
1992,
Pubmed
Filizola,
3D modeling, ligand binding and activation studies of the cloned mouse delta, mu; and kappa opioid receptors.
1999,
Pubmed
Fukuda,
Identification of the amino acid residues involved in selective agonist binding in the first extracellular loop of the delta- and mu-opioid receptors.
1995,
Pubmed
Ikeda,
Functional couplings of the delta- and the kappa-opioid receptors with the G-protein-activated K+ channel.
1995,
Pubmed
,
Xenbase
Kieffer,
The delta-opioid receptor: isolation of a cDNA by expression cloning and pharmacological characterization.
1992,
Pubmed
Kieffer,
Opioids: first lessons from knockout mice.
1999,
Pubmed
Knapp,
Molecular biology and pharmacology of cloned opioid receptors.
1995,
Pubmed
Kobayashi,
Molecular cloning of a mouse G-protein-activated K+ channel (mGIRK1) and distinct distributions of three GIRK (GIRK1, 2 and 3) mRNAs in mouse brain.
1995,
Pubmed
Kofuji,
Evidence that neuronal G-protein-gated inwardly rectifying K+ channels are activated by G beta gamma subunits and function as heteromultimers.
1995,
Pubmed
,
Xenbase
Krieg,
Functional messenger RNAs are produced by SP6 in vitro transcription of cloned cDNAs.
1984,
Pubmed
,
Xenbase
Law,
Mutational analysis of the structure and function of opioid receptors.
1999,
Pubmed
Li,
ASP147 in the third transmembrane helix of the rat mu opioid receptor forms ion-pairing with morphine and naltrexone.
1999,
Pubmed
Li,
delta-Opioid receptor: the third extracellular loop determines naltrindole selectivity.
1996,
Pubmed
Liman,
Subunit stoichiometry of a mammalian K+ channel determined by construction of multimeric cDNAs.
1992,
Pubmed
,
Xenbase
Lomize,
Structural organization of G-protein-coupled receptors.
1999,
Pubmed
Mansour,
Key residues defining the mu-opioid receptor binding pocket: a site-directed mutagenesis study.
1997,
Pubmed
McFadyen,
The steroid 17alpha-acetoxy-6-dimethylaminomethyl-21-fluoro-3-ethoxy-pregna-3, 5-dien-20-one (SC17599) is a selective mu-opioid agonist: implications for the mu-opioid pharmacophore.
2000,
Pubmed
Meng,
A chimeric study of the molecular basis of affinity and selectivity of the kappa and the delta opioid receptors. Potential role of extracellular domains.
1995,
Pubmed
Minami,
A single residue, Lys108, of the delta-opioid receptor prevents the mu-opioid-selective ligand [D-Ala2,N-MePhe4,Gly-ol5]enkephalin from binding to the delta-opioid receptor.
1996,
Pubmed
Minami,
DAMGO, a mu-opioid receptor selective ligand, distinguishes between mu-and kappa-opioid receptors at a different region from that for the distinction between mu- and delta-opioid receptors.
1995,
Pubmed
Mollereau,
Distinct mechanisms for activation of the opioid receptor-like 1 and kappa-opioid receptors by nociceptin and dynorphin A.
1999,
Pubmed
Onogi,
DAMGO, a mu-opioid receptor selective agonist, distinguishes between mu- and delta-opioid receptors around their first extracellular loops.
1995,
Pubmed
Pogozheva,
Opioid receptor three-dimensional structures from distance geometry calculations with hydrogen bonding constraints.
1998,
Pubmed
Seki,
DAMGO recognizes four residues in the third extracellular loop to discriminate between mu- and kappa-opioid receptors.
1998,
Pubmed
Spivak,
Naloxone activation of mu-opioid receptors mutated at a histidine residue lining the opioid binding cavity.
1997,
Pubmed
,
Xenbase
Subramanian,
Molecular docking reveals a novel binding site model for fentanyl at the mu-opioid receptor.
2000,
Pubmed
Ulens,
Interaction of p-fluorofentanyl on cloned human opioid receptors and exploration of the role of Trp-318 and His-319 in mu-opioid receptor selectivity.
2000,
Pubmed
,
Xenbase
Ulens,
Changes in GIRK1/GIRK2 deactivation kinetics and basal activity in the presence and absence of RGS4.
2000,
Pubmed
,
Xenbase
Ulens,
Morphine-6beta-glucuronide and morphine-3-glucuronide, opioid receptor agonists with different potencies.
2001,
Pubmed
,
Xenbase
Wang,
mu opiate receptor: cDNA cloning and expression.
1993,
Pubmed
Wang,
Human kappa opiate receptor second extracellular loop elevates dynorphin's affinity for human mu/kappa chimeras.
1994,
Pubmed
Wang,
Studies on mu and delta opioid receptor selectivity utilizing chimeric and site-mutagenized receptors.
1995,
Pubmed
Xu,
Functional role of the spatial proximity of Asp114(2.50) in TMH 2 and Asn332(7.49) in TMH 7 of the mu opioid receptor.
1999,
Pubmed
Xu,
The conserved cysteine 7.38 residue is differentially accessible in the binding-site crevices of the mu, delta, and kappa opioid receptors.
2000,
Pubmed